Jubilant Life Sciences, on Friday, reported a net loss of ₹100.65 crore in the fourth quarter, ended March 31, 2019 on account of a one-time loan settlement with International Finance Corporation (IFC).

The company had posted a consolidated net profit of ₹152.40 crore an year ago, Jubilant Life Sciences said in a regulatory filing.

Jubilant Life Sciences said its bottomline in the quarter was hit by a one-time loan settlement with IFC, that resulted in an exceptional item of ₹234.76 crore for the quarter ended March 31.

Its consolidated total income during the fourth quarter ended March 31, 2019, stood at ₹2,379 crore as compared to ₹2,274.87 crore last year.

Jubilant Life Sciences total expenses was higher at ₹2,184.22 crore as compared to ₹2,048.31 crore in the year-ago quarter.

“The company witnessed healthy performance during the quarter, which was offset by certain one-time charges,” said Shyam S Bhartia, Chairman of Jubilant Life Sciences and Hari S Bhartia, Co-Chairman & Managing Director, added that the company remains focused on generating operating cash and investing it to support the company’s growth and reduce debt.

For the financial year 2018-19 ended March 31, the company had a net profit of ₹577.01 crore as compared to ₹634.42 crore in the previous fiscal.

Total income for the year stands at ₹9,146.56 crore as against ₹7,597.84 crore in the previous fiscal.

Jubilant Life Science expects stable performance in FY20.

“The pharma segment is expected to continue to deliver steady revenues with range bound margins across businesses,” it said.

Related Topics
comment COMMENT NOW